Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 生物資源暨農學院
  3. 獸醫專業學院
  4. 臨床動物醫學研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57624
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor林中天
dc.contributor.authorTing-Chun Kuoen
dc.contributor.author郭亭君zh_TW
dc.date.accessioned2021-06-16T06:54:41Z-
dc.date.available2017-07-29
dc.date.copyright2014-07-29
dc.date.issued2014
dc.date.submitted2014-07-20
dc.identifier.citationAhmad, S., Wallace, D. J., & Herndon, L. W. (2008). Phthisis after endoscopic cyclophotocoagulation. Ophthalmic Surg Lasers Imaging, 39(5), 407-408.
Aujla, J. S., Lee, G. A., Vincent, S. J., & Thomas, R. (2013). Incidence of hypotony and sympathetic ophthalmia following trans-scleral cyclophotocoagulation for glaucoma and a report of risk factors. Clin Experiment Ophthalmol, 41(8), 761-772
Bloom, P. A., & Dharmaraj, S. (2006). Endoscopic and transscleral cyclophotocoagulation. Br J Ophthalmol, 90(6), 666-668.
Bloom, P. A., Clement, C. I., King, A., Noureddin, B., Sharma, K., Hitchings, R. A., & Khaw, P. T. (2013). A comparison between tube surgery, ND:YAG laser and diode laser cyclophotocoagulation in the management of refractory glaucoma. Biomed Res Int, 2013, 371951.
Bloom, P. (2008). ECP has role as both primary and secondary glaucoma treatment. Ocul surg news, 19(9), 32-32.
Boyle, E. L. (2008). ECP lowers IOP with and without cataract surgery. Ocul surg news, 19(11), 22-22.
Brubaker, R. F. (1996). Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol, 121(5), 473-483.
Budenz, D. L., & Gedde, S. J. (2014). New options for combined cataract and glaucoma surgery. Curr Opin Ophthalmol, 25(2), 141-147.
Carter, B. C., Plager, D. A., Neely, D. E., Sprunger, D. T., Sondhi, N., & Roberts, G. J. (2007). Endoscopic diode laser cyclophotocoagulation in the management of aphakic and pseudophakic glaucoma in children. J aapos, 11(1), 34-40.
Arici, M. K., Arici, D. S., Topalkara, A., & Guler, C. (2000). Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Experiment Ophthalmol, 28(2), 113-117.
Blocker, T., Hoffman, A., Schaeffer, D. J., & Wallin, J. A. (2007). Corneal sensitivity and aqueous tear production in dogs undergoing evisceration with intraocular prosthesis placement. Vet Ophthalmol, 10(3), 147-154.
Chander, A., Kapoor, H., & Thomas, S. (2013). Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma. Nepal J Ophthalmol, 5(9), 75-80.
Duke, F. D., Strong, T. D., Bentley, E., & Dubielzig, R. R. (2013). Canine ocular tumors following ciliary body ablation with intravitreal gentamicin. Vet Ophthalmol, 16(2), 159-162.
Egbert, P. R., Fiadoyor, S., Budenz, D. L., Dadzie, P., & Byrd, S. (2001). Diode laser transscleral cyclophotocoagulation as a primary surgical treatment for primary open-angle glaucoma. Arch Ophthalmol, 119(3), 345-350.
Gelatt, K. N., & MacKay, E. O. (2001). Changes in intraocular pressure associated with topical dorzolamide and oral methazolamide in glaucomatous dogs. Vet Ophthalmol, 4(1), 61-67.
Grozdanic, S. D., Matic, M., Betts, D. M., Sakaguchi, D. S., & Kardon, R. H. (2007). Recovery of canine retina and optic nerve function after acute elevation of intraocular pressure: implications for canine glaucoma treatment. Vet Ophthalmol, 10 Suppl 1, 101-107.
Guinan, J., Willis, A. M., Cullen, C. L., & Walshaw, R. (2007). Postenucleation orbital sialocele in a dog associated with prior parotid duct transposition. Vet Ophthalmol, 10(6), 386-389.
Hardman, C., & Stanley, R. G. (2001). Diode laser transscleral cyclophotocoagulation for the treatment of primary glaucoma in 18 dogs: a retrospective study. Vet Ophthalmol, 4(3), 209-215.
Ichhpujani, P., & Ramasubramanian, A. (2009). Ocular surface changes with long-term topical antiglaucoma medications. J Curr Glaucoma Prac, 3(3), 19-26.
Ishida, K. (2013). Update on results and complications of cyclophotocoagulation. Curr Opin Ophthalmol, 24(2), 102-110.
Jeng, Y. Y., Chang, P. H., Yeh, L. S., & Lin, C. T. (2004). The effects on intraocular pessure with intravitreal injection of cyclodestructive gentamicin in dogs with persistent glaucoma. Taiwan Vet J, 30(3), 188-192.
Maggs, D. J., & Kass, P. H. (2006). Evaluation of risk factors for development of secondary glaucoma in dogs: 156 cases (1999-2004). J Am Vet Med Assoc, 229(8), 1270-1274.
Kahook, M. Y., Lathrop, K. L., & Noecker, R. J. (2007). One-site versus two-site endoscopic cyclophotocoagulation. J Glaucoma, 16(6), 527-530.
Kato, K., Sasaki, N., Matsunaga, S., Nishimura, R., & Ogawa, H. (2006). Incidence of canine glaucoma with goniodysplasia in Japan : a retrospective study. J Vet Med Sci, 68(8), 853-858.
Kramp, K., Vick, H. P., & Guthoff, R. (2002). Transscleral diode laser contact cyclophotocoagulation in the treatment of different glaucomas, also as primary surgery. Graefes Arch Clin Exp Ophthalmol, 240(9), 698-703.
Lin, C. T., Hu, C. K., Liu, C. H., & Yeh, L. S. (2007). Surgical outcome and ocular complications of evisceration and intraocular prosthesis implantation in dogs with end stage glaucoma: a review of 20 cases. J Vet Med Sci, 69(8), 847-850.
Lin, S. C. (2008). Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma. J Glaucoma, 17(3), 238-247.
Miller, P. E., Schmidt, G. M., Vainisi, S. J., Swanson, J. F., & Herrmann, M. K. (2000). The efficacy of topical prophylactic antiglaucoma therapy in primary closed angle glaucoma in dogs: a multicenter clinical trial. J Am Anim Hosp Assoc, 36(5), 431-438.
Noureddin, B. N., Zein, W., Haddad, C., Ma'luf, R., & Bashshur, Z. (2006). Diode laser transcleral cyclophotocoagulation for refractory glaucoma: a 1 year follow-up of patients treated using an aggressive protocol. Eye (Lond), 20(3), 329-335.
Osborne, N. N., Ugarte, M., Chao, M., Chidlow, G., Bae, J. H., Wood, J. P., & Nash, M. S. (1999). Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol, 43 Suppl 1, S102-128.
Sapienza, J. S., & van der Woerdt, A. (2005). Combined transscleral diode laser cyclophotocoagulation and Ahmed gonioimplantation in dogs with primary glaucoma: 51 cases (1996-2004). Vet Ophthalmol, 8(2), 121-127.
Sarup, V., McEwan, G. C., Thompson, C., Patil, K. A., & Sharma, S. C. (2005). Dorzolamide and timolol saves retinal ganglion cells in glaucomatous adult rats. J Ocul Pharmacol Ther, 21(6), 454-462.
Strom, A. R., Hassig, M., Iburg, T. M., & Spiess, B. M. (2011a). Epidemiology of canine glaucoma presented to University of Zurich from 1995 to 2009. Part 1: Congenital and primary glaucoma (4 and 123 cases). Vet Ophthalmol, 14(2), 121-126.
Strom, A. R., Hassig, M., Iburg, T. M., & Spiess, B. M. (2011b). Epidemiology of canine glaucoma presented to University of Zurich from 1995 to 2009. Part 2: secondary glaucoma (217 cases). Vet Ophthalmol, 14(2), 127-132.
Westermeyer, H. D., Hendrix, D. V., & Ward, D. A. (2011). Long-term evaluation of the use of Ahmed gonioimplants in dogs with primary glaucoma: nine cases (2000-2008). J Am Vet Med Assoc, 238(5), 610-617.
Yip, L. W., Yong, S. O., Earnest, A., Ji, J., & Lim, B. A. (2009). Endoscopic cyclophotocoagulation for the treatment of glaucoma: an Asian experience. Clin Experiment Ophthalmol, 37(7), 692-697.
陳以瑛 (2011):局部抗青光眼藥、全身性神經保護藥物與抗氧化營養添加物對高眼壓傷害之大鼠視網膜的保護效力研究。國立台灣大學獸醫學研究所碩士論文。
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57624-
dc.description.abstract青光眼會造成患犬疼痛以及視力不可逆地受損,亦為犬隻進行眼球摘除手術的適應症之一。青光眼是一多因子的疾病,當眼房液生成增加或者排除受阻導致眼內壓上升,進一步影響眼內健康與視力時即可稱之。青光眼最佳治療方式仍有爭議性,部分學者認為手術介入對於眼內壓的控制有最直接的效果。破壞睫狀體的手術方式常被用於治療頑固性、對內科療法反應不佳的青光眼病畜。經鞏膜二極體雷射光凝術 (Diode laser transscleral cyclophotocoagulation, TSCP) 是一不具侵略性併發症較少的手術方式,近年來新興的治療方式為藉助內視鏡引導直接進入眼內燒灼睫狀體的內視鏡二極體雷射光凝術 (Endoscopic CPC, ECP),由於後者被認為有更清楚的手術視野而漸受重視。
本研究的目的為回溯性分析自2004年1月1日起至2014年1月1日止就診於台灣大學動物醫院眼科門診與遠見動物眼科專科醫院之頑固性或末期青光眼的患犬,並探討不同治療方式的成效及術後併發症等。搜集資料後依照病畜選擇的治療方式區分為單純接受藥物治療 (Medical treatment only, MO)、經鞏膜二極體雷射光凝術 (TSCP)、內視鏡二極體雷射光凝術 (ECP)、眼內容物移除與人工義眼置換術 (Evisceration and intraocular prosthesis implantation, ISP) 以及眼球摘除術 (Enucleation, E) 共5個群組。針對僅接受藥物治療的青光眼患犬除了記錄其品種、性別、發病年齡、眼內壓數值、追蹤期長短與是否有其他眼科相關疾病外,亦記錄追蹤期間所給予的降眼壓藥物以及其預後;針對有手術介入治療的群組,其分析項目除了上述之外,再加入手術時的雷射設定與術後併發症的記錄。
本研究共計包含204隻犬、239隻末期青光眼被列入分析,患犬被列入研究時的年齡介於0.1至18歲 (平均8.9 ± 4.2歲)。品種分布方面共計有30個品種,出現頻率較高者依序為瑪爾濟斯 (39/204, 19.1%)、混種犬(35/204, 17.1%)、西施犬 (22/204, 10.8%)、柴犬 (15/204, 7.4%) 以及貴賓犬 (12/204, 5.9%)。共包括26隻已絕育公犬、49隻公犬、74隻已絕育母犬以及55隻母犬。平均追蹤期為480.8 ± 477.7天。原發性青光眼、繼發性青光眼以及因多重眼內病變無法確認青光眼病因者分別占106、102與31隻眼睛。在青光眼控制成功被定義為眼內壓下降幅度大於或等於20%且抗青光眼藥物的使用得以減少的條件下,MO、TSCP以及ECP群組的成功率依序為25.2%、57.1%以及92.9%。比較不同群組間成功率的相關性,MO與ECP群組的成功率有顯著差異性 (p value = 0.000 < 0.05),而MO與TSCP群組的成功率則無顯著差異性 (p value = 0.061 > 0.05)。
TSCP、ECP、ISP與E群組的術後併發症機率依序為57.1%、64.3%、60.5%以及0%。術後併發症包括乾眼症、水晶體不全異位或異位、角膜潰瘍、眼球萎縮、眼內出血、角膜缺損、角膜肉芽反應以及角膜水腫。大多數的術後併發症皆為輕微且自限性的,在最後一次複診時皆能完全復原或得到緩解並未出現病畜眼睛不適的症狀。
ECP可能是一個針對頑固性末期青光眼患犬有效的治療方式。本研究中,相較於TSCP或MO群組,ECP可以顯著降低眼內壓並且減少術後抗青光眼藥物的使用。
zh_TW
dc.description.abstractGlaucoma is not only one of the leading causes of irreversible blindness and ocular pain in dogs but also the most common reason for enucleation in dogs. Traditionally glaucoma has been defined as a group of ocular diseases that exhibit increased levels of intraocular pressure (IOP) that are detrimental to the vision and health of the eye.
The most successful therapy for control of glaucoma still remains debatable. Most veterinary ophthalmologists believe that surgery is the best route to reach a target range of IOP. Cyclodestructive procedures are usually reserved for cases of glaucoma that are refractory to medical therapy. Diode laser transscleral cyclophotocoagulation (TSCP) is a noninvasive procedure with a low complication rate. A newer method to directly photocoagulate the ciliary body under endoscopic guidance known as endoscopic CPC (ECP) has become an increasingly important and may have distinct advantages over the transscleral approach in eyes.
The purpose of the study was to investigate the efficacy and complications of different treatments for dogs with persistent glaucoma presented to the ophthalmology clinic of the National Taiwan University Veterinary Hospital (NTUVH) and Vision Eyecare Center for Animals, Taipei from January 1st, 2004 to January 1st, 2014. The data was evaluated for breed, gender, and age at presentation. Medications for the glaucoma patients, prognosis for conservative and/or different surgical treatments (including TSCP, ECP, evisceration and intraocular prosthesis implantation, and enucleation) are also recorded.
Efficacy and complications of different treatments for 204 dogs (239eyes) with persistent glaucoma were analyzed. The age of the dogs ranged between 0.1 and 18 years (mean 8.9 ± 4.2 years) . Thirty breeds were represented, with the five leading affected breeds being Maltese (39/204, 19.1%) , cross-bred (35/204, 17.1%) , Shih-Tzu (22/204, 10.8%) , Shiba Inu (15/204, 7.4%) , and Poodle (12/204, 5.9%) . The gender distribution was 26 neutered male, 49 intact male, 74 spayed female, and 55 intact female. The mean follow-up duration was 480.8 ± 477.7 days. Primary glaucoma, secondary glaucoma and glaucoma of unknown etiology was diagnosed in 106, 102 and 31 eyes, respectively. The success rate based on IOP reduction of 20% or greater with a decrease in the number of antiglaucoma medications from baseline at last follow-up was 25.2%, 57.1%, and 92.9% respectively in medical treatment only (MO), transscleral cyclophotocoagulation (TSCP), and endoscopic cyclophotocoagulation (ECP) group. Statistically significant difference of success rate was found between MO and ECP group (p value = 0.000 < 0.05) but not between MO and TSCP group (p value = 0.061 > 0.05) .
The complication rate of 57.1%, 64.3%, 60.5%, and 0% was in the groups of TSCP, ECP, evisceration and intraocular prosthesis implantation (ISP) , and enucleation (E) group, respectively. Post-operative complications of these surgeries included keratoconjunctivitis sicca (KCS) , lens subluxation / luxation, corneal ulcer, phthisis bulbus, hyphema, cornea defect, cornea granulation, and cornea edema. The majority of complications were minimal and self-limited and recovered or relieved at last follow-up without signs of discomfort in treated patients.
ECP may be an effective treatment for dogs with persistent glaucoma. In this study, ECP was associated with the greatest IOP control and marked decrease in the needs of prescribed antiglaucoma medications at last evaluation compared with MO or TSCP group.
en
dc.description.provenanceMade available in DSpace on 2021-06-16T06:54:41Z (GMT). No. of bitstreams: 1
ntu-103-R01643004-1.pdf: 2565595 bytes, checksum: a1013c59c80ec21e0a4a01fbdf58fe7c (MD5)
Previous issue date: 2014
en
dc.description.tableofcontents口試委員會審定書 #
中文摘要 i
ABSTRACT iii
目錄 vi
圖目錄 x
表目錄 xiii
Chapter 1 序論 1
1.1 前言 1
1.2 研究目的 1
Chapter 2 文獻探討 2
2.1 青光眼疾病介紹與治療 2
2.2 抗青光眼降眼壓藥物及神經保護藥物 5
2.2.1 Beta受體阻斷劑 (Beta - blocker) 5
2.2.2 擬副交感類藥物 (Parasympatho - mimetic Agents) 5
2.2.3 碳酸酐酶抑制劑 (Carbonic Anhydrase Inhibitors,
CAIs) 6
2.2.4 前列腺素相似物 (Prostaglandin Analogs) 6
2.2.5 神經保護藥物 (Neuroprotective Drugs) 7
2.3 青光眼的流行病學調查 7
2.4 人工眼前房液的壓力閥引流裝置 (Artificial aqueous
humor shunts, gonioimplant) 9
2.5 應用於動物眼科疾病的雷射治療 9
2.5.1 雷射手術的原理與分類 9
2.5.2 雷射的吸收率與組織穿透力 10
2.5.3 雷射的設定 11
2.6 經鞏膜二極體雷射光凝術 (Diode Laser Transscleral
Cyclophotocoagulation, TSCP) 12
2.7 內視鏡二極體雷射光凝術 (Diode Laser Endoscopic
Cyclophotocoagulation, ECP) 13
2.7.1 內視鏡二極體雷射光凝術於動物青光眼治療的應用 13
2.7.2 內視鏡二極體雷射光凝術於人青光眼治療的應用 15
2.8 其他睫狀體破壞手術 17
2.8.1 睫狀體冷凍治療 (Cyclocryotherapy) 17
2.8.2 化學消融療法(Chemical Ablation) 18
2.9 眼內容物移除與人工義眼置換術 (Evisceration and
Intraocular Prosthesis Implantation, ISP) 20
2.10 眼球摘除術 (Enucleation) 22
Chapter 3 實驗材料與方法 23
3.1 實驗架構 23
3.2 病歷蒐集 23
3.2.1 研究對象 (Inclusion Criteria) 23
3.2.2 病歷資料分組 23
3.2.3 記錄項目 24
3.2.4 青光眼控制成功之定義 24
3.2.5 青光眼病因的診斷與分類 24
3.2.6 抗青光眼藥物的種類 25
3.2.7 雷射光凝術使用儀器 25
3.3 資料分析 27
Chapter 4 實驗結果 28
4.1 基本資料 28
4.2 青光眼的病因與其他眼內疾病 30
4.3 MO, TSCP & ECP青光眼控制成功率 31
4.4 TSCP, ECP, ISP & E術後併發症與相關性 32
4.5 ECP群組之分析 33
4.5.1 ECP術後眼內壓平均值曲線圖 34
4.5.2 ECP術後抗青光眼藥物 - Cosopt &reg;平均使用頻率曲線圖 36
4.5.3 ECP術後抗青光眼藥物 - 前列腺素相似物 PG (Xalatan&reg;
& Travatan&reg;) 平均使用頻率曲線圖 36
4.5.4 ECP術後抗青光眼藥物 - Cosopt &reg; 使用總比例曲線圖 37
4.5.5 ECP術後抗青光眼藥物- 前列腺素相似物 PG (Xalatan&reg;
& Travatan&reg;) 使用總比例曲線圖 37
4.6 原發性青光眼患犬之統計分析 42
4.6.1 原發性青光眼患犬的基本資料 42
4.6.2 原發性青光眼患犬其他的眼內疾病 44
4.6.3 MO, TSCP & ECP群組中原發性青光眼控制成功率 45
4.6.4 TSCP, ECP, ISP & E 群組中原發性青光眼患犬術後併發
症與相關性 46
Chapter 5 討論 48
5.1 基本資料 48
5.2 青光眼的病因與其他眼內疾病 49
5.3 MO, TSCP & ECP青光眼控制成功率 51
5.4 TSCP, ECP, ISP & E術後併發症與相關性 53
5.5 ECP群組之分析 57
5.6 本研究的限制 58
Chapter 6 結論 61
參考文獻 63
dc.language.isozh-TW
dc.title台灣犬隻頑固性青光眼不同治療方法的成效比較zh_TW
dc.titleComparison of Management Outcome of Canine Persistent Glaucoma in Taiwanen
dc.typeThesis
dc.date.schoolyear102-2
dc.description.degree碩士
dc.contributor.oralexamcommittee葉力森,林荀龍
dc.subject.keyword青光眼,經鞏膜二極體雷射光凝術,內視鏡二極體雷射光凝術,人工義眼置換術,zh_TW
dc.subject.keywordGlaucoma,Diode laser transscleral cyclophotocoagulation,Diode laser endoscopic cyclophotocoagulation,Intraocular prosthesis implantation,en
dc.relation.page65
dc.rights.note有償授權
dc.date.accepted2014-07-21
dc.contributor.author-college獸醫專業學院zh_TW
dc.contributor.author-dept臨床動物醫學研究所zh_TW
顯示於系所單位:臨床動物醫學研究所

文件中的檔案:
檔案 大小格式 
ntu-103-1.pdf
  目前未授權公開取用
2.51 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved